Septerna, Inc.

NasdaqGM:SEPN Stock Report

Market Cap: US$1.1b

Septerna Future Growth

Future criteria checks 0/6

Septerna's earnings are forecast to decline at 26.8% per annum while its annual revenue is expected to grow at 5.3% per year. EPS is expected to decline by 21.2% per annum. Return on equity is forecast to be -29.3% in 3 years.

Key information

-26.8%

Earnings growth rate

-21.18%

EPS growth rate

Pharmaceuticals earnings growth14.5%
Revenue growth rate5.3%
Future return on equity-29.27%
Analyst coverage

Good

Last updated30 Apr 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Nov 25

Septerna's Novo Partnership Begins To Transform The Story

Summary Septerna, Inc. delivered a strong 3Q25, driven by partnership revenue from its transformative collaboration with Novo Nordisk. SEPN's Novo partnership brings $195M upfront, a potential $2.2B in milestones, and full R&D funding, reducing capital burden and boosting strategic position. The incretin-pathway GPCR program is closest to early milestones, with further upside tied to successful target validation and hit-to-lead advancements. Despite elevated valuation multiples, SEPN's robust cash position and pipeline progress support a bullish outlook, though volatility and long timelines remain. Read the full article on Seeking Alpha
Analysis Article • Oct 05

We're Not Worried About Septerna's (NASDAQ:SEPN) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Apr 28

Companies Like Septerna (NASDAQ:SEPN) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 04

Septerna: Great In Theory, Needs Proof

Summary Septerna's Native Complex platform isolates GPCRs in their native form, enabling advanced drug discovery for previously undruggable targets, including oral small-molecule therapeutics. Lead molecule SEP-786 targets hypoparathyroidism, showing promising preclinical results and entering phase 1 trials, with data expected in mid-2025. SEPN has a $750mn market cap and $130mn in cash, providing a 6-7 quarter runway, but lacks clinical data until 2025. Despite the innovative platform, I recommend waiting for phase 1 data before investing due to the current lack of clinical proof. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGM:SEPN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202853-162-145-1696
12/31/202760-130-122-1279
12/31/202666-89-91-1209
12/31/202546-49110110N/A
9/30/202522-59103104N/A
6/30/20251-88-83-81N/A
3/31/20251-79-76-74N/A
12/31/20241-72-70-67N/A
9/30/20241-20-58-55N/A
6/30/20241-10-51-48N/A
3/31/20240-4-48-45N/A
12/31/202301-42-39N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SEPN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SEPN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SEPN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SEPN's revenue (5.3% per year) is forecast to grow slower than the US market (11.6% per year).

High Growth Revenue: SEPN's revenue (5.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SEPN is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/11 19:56
End of Day Share Price 2026/05/08 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Septerna, Inc. is covered by 9 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Raghuram SelvarajuH.C. Wainwright & Co.
Catherine NovackJonesTrading Institutional Services, LLC